2 results
Approved WMOCompleted
Primary:* To determine the effect of vedolizumab IV compared to adalimumab SC on clinical remission at Week 52.Secondary:* To evaluate the effect of vedolizumab IV compared to adalimumab SC on mucosal healing at Week 52.* To evaluate the effect of…
Approved WMORecruiting
To evaluate the immediate impact of TAVI or TMVr on a battery of coronary (non-) hyperemic physiology tests in patient with severe aortic valve stenosis or functional/degenerative mitral regurgitation and at least intermediate coronary artery…